FTC, diet pill marketers settle for $25M

Jan 05, 2007

The U.S. Federal Trade Commission recovered $25 million as a settlement in its cases alleging deceptive advertising against marketers of four diet pills.

The FTC filed separate cases against the marketers, alleging that claims about weight loss and weight control were not supported by scientific evidence. In settling the matters, marketers of Xenadrine EFX, CortiSlim, TrimSpa, and One-A-Day WeightSmart surrendered cash and other assets worth at least $25 million and agreed to limit their future advertised claims, the agency said in a news release.

"You won't find weight loss in a bottle of pills that claims it has the latest scientific breakthrough or miracle ingredient," said FTC Chairman Deborah Platt Majoras. "Paying for fad science is a good way to lose cash, not pounds."

Besides fines and penalties, the settlements also stipulated that the marketers are barred from making claims regarding the products' benefits unless the claims can be substantiated by scientific evidence.

The FTC said the National Advertising Division of the Council of Better Business Bureaus referred some of these cases.

Copyright 2007 by United Press International

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

US online child privacy get stricter

Jul 01, 2013

Toughened US regulations on online privacy for children take effect Monday, offering new protections amid the growing use of mobile apps and social networks by youngsters.

Microsoft renews plea for crackdown on Google

Jan 02, 2013

Microsoft began the new year harping on a favorite theme: The software maker is arguing that government regulators need to crack down on Google to preserve fair competition in the Internet and smartphone markets.

Google faces moment of truth on monopoly probe

Oct 21, 2012

Google faces a moment of truth in the coming weeks over a lengthy US probe into potential abuse of its Internet search dominance, amid regulatory woes on both sides of the Atlantic.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Sensors may keep hospitalized patients from falling

(Medical Xpress)—To keep hospitalized patients safer, University of Arizona researchers are working on new technology that involves a small, wearable sensor that measures a patient's activity, heart rate, ...

Fresh hope for preventing pneumonia in the elderly

There are calls for the frail and elderly not be be overlooked for vaccines against pneumonia this winter, with UNSW research challenging conventional wisdom on immunisation effectiveness in older patients.

Phase transiting to a new quantum universe

(Phys.org) —Recent insight and discovery of a new class of quantum transition opens the way for a whole new subfield of materials physics and quantum technologies.

Imaging turns a corner

(Phys.org) —Scientists have developed a new microscope which enables a dramatically improved view of biological cells.

NASA image: Volcanoes in Guatemala

This photo of volcanoes in Guatemala was taken from NASA's C-20A aircraft during a four-week Earth science radar imaging mission deployment over Central and South America. The conical volcano in the center ...